AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Recruiting participants (Starts Jun. 14, 2017)
Not accepting healthy volunteers
UTSW Principal Investigator: Tamra Lynn Slone
Participate
If you are interested in this clinical trial, please contact Anil Shalwani on the Children’s Health Research Team.Call 214-456-7353Email
STU 062017-028
AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)